# RADIOACTIVE LABELING OF BLOOD CELLS AND THEIR PRODUCTS

> **NIH NIH R01** · UPSTATE MEDICAL UNIVERSITY · 1988 · $221,624

## Abstract

This project seeks to improve the current methods of labeling leukocytes
and platelets with gamma-emitting agents for the delineation of focal
inflammatory lesions, endothelial injury and thrombi by scintillation
camera imaging.  New radiopharmaceuticals will be developed, including
analogues of 8-hydroxyquinoline, disulphide compounds and
bis-thiosemicarbazones.  These lipophilic chelating agents will be labeled
with 99mTc, 111In, 197Hg, 203Pb or 97Ru.  A continuous flow elutriation
system with a special centrifuge rotor will be used to harvest leukocytes
and centrifugation with Metrizamide or Stractan density gradients will be
used to harvest platelets.  Viability of the isolated labeled cells will be
assessed by reinjection into experimental animals and measurement of cell
recovery and survival in the blood stream.  Their efficacy in demonstrating
focal inflammatory lesions and vascular damage will be assessed in animals
by gamma camera imaging and by direct tissue radioassay.

## Key facts

- **NIH application ID:** 3170705
- **Project number:** 5R01CA032853-12
- **Recipient organization:** UPSTATE MEDICAL UNIVERSITY
- **SAM.gov UEI:** HYN3WD58HNN7
- **Principal Investigator:** JOHN G. MC AFEE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $221,624
- **Award type:** 5
- **Project period:** 1980-01-01 → 1989-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3170705

## Citation

> US National Institutes of Health, RePORTER application 3170705, RADIOACTIVE LABELING OF BLOOD CELLS AND THEIR PRODUCTS (5R01CA032853-12). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3170705. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*